HK1112006A1 - Antibodies against il-13 receptor alpha 1 and uses thereof - Google Patents
Antibodies against il-13 receptor alpha 1 and uses thereofInfo
- Publication number
- HK1112006A1 HK1112006A1 HK08106940.0A HK08106940A HK1112006A1 HK 1112006 A1 HK1112006 A1 HK 1112006A1 HK 08106940 A HK08106940 A HK 08106940A HK 1112006 A1 HK1112006 A1 HK 1112006A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibodies against
- receptor alpha
- receptor
- alpha
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05000003 | 2005-01-03 | ||
EP05002229 | 2005-02-03 | ||
PCT/EP2006/000005 WO2006072564A1 (fr) | 2005-01-03 | 2006-01-02 | Anticorps contre le recepteur alpha-1 de l'il-13 et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1112006A1 true HK1112006A1 (en) | 2008-08-22 |
Family
ID=36199730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08106940.0A HK1112006A1 (en) | 2005-01-03 | 2008-06-23 | Antibodies against il-13 receptor alpha 1 and uses thereof |
Country Status (20)
Country | Link |
---|---|
US (2) | US7807158B2 (fr) |
EP (1) | EP1836226B1 (fr) |
JP (1) | JP5086098B2 (fr) |
KR (1) | KR100934894B1 (fr) |
AR (1) | AR051888A1 (fr) |
AT (1) | ATE513855T1 (fr) |
AU (1) | AU2006204480B2 (fr) |
BR (1) | BRPI0606368A2 (fr) |
CA (1) | CA2592614C (fr) |
CR (1) | CR9209A (fr) |
HK (1) | HK1112006A1 (fr) |
IL (1) | IL184205A0 (fr) |
MA (1) | MA29226B1 (fr) |
MX (1) | MX2007008128A (fr) |
NO (1) | NO20073655L (fr) |
NZ (1) | NZ556126A (fr) |
RU (1) | RU2413736C2 (fr) |
SG (1) | SG172504A1 (fr) |
TW (2) | TW200902555A (fr) |
WO (1) | WO2006072564A1 (fr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
MY149079A (en) * | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
ES2388567T3 (es) | 2006-10-19 | 2012-10-16 | Csl Limited | Anticuerpos anti-il-13r alfa 1 y usos de los mismos |
JP2010507366A (ja) * | 2006-10-19 | 2010-03-11 | メルク アンド カンパニー インコーポレイテッド | インターロイキン−13受容体α1の抗体アンタゴニスト |
EP2068921B1 (fr) | 2006-10-19 | 2014-07-09 | CSL Limited | Anticorps antagonistes de haute affinité dirigés contre le récepteur alpha 1 de l'interleukine-13 |
CA2687837A1 (fr) | 2007-06-01 | 2008-12-04 | F. Hoffmann-La Roche Ag | Purification d'une immunoglobuline |
EP2167127A1 (fr) * | 2007-07-10 | 2010-03-31 | F. Hoffmann-Roche AG | Nouvelle formulation |
HUE039950T2 (hu) | 2007-10-12 | 2019-02-28 | Hoffmann La Roche | Fehérjeexpresszió több nukleinsavból |
EP2050764A1 (fr) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Nouveau format d'anticorps bispécifique polyvalent |
ES2407603T3 (es) | 2007-12-15 | 2013-06-13 | F. Hoffmann-La Roche Ag | Ensayo de distinción |
KR101830024B1 (ko) * | 2009-03-25 | 2018-02-19 | 제넨테크, 인크. | 항-fgfr3 항체 및 그의 사용 방법 |
WO2010131704A1 (fr) * | 2009-05-13 | 2010-11-18 | 塩野義製薬株式会社 | Agent d'essai pour l'obésité viscérale et son utilisation |
WO2011012296A1 (fr) | 2009-07-30 | 2011-02-03 | F. Hoffmann-La Roche Ag | Séparateur mobile pour colonne chromatographique |
WO2011038894A1 (fr) | 2009-10-01 | 2011-04-07 | F. Hoffmann-La Roche Ag | Chromatographie sur protéine a |
PL2483305T3 (pl) | 2009-10-01 | 2017-03-31 | F.Hoffmann-La Roche Ag | Wieloetapowa końcowa filtracja immunoglobuliny |
AU2010309931B2 (en) | 2009-10-19 | 2015-08-20 | F. Hoffmann-La Roche Ag | Non-cross-reactive anti IgG antibodies |
CN102666582B (zh) | 2009-12-22 | 2016-03-30 | 弗·哈夫曼-拉罗切有限公司 | 序列依赖性聚集 |
EP2606071B1 (fr) | 2010-08-17 | 2019-12-18 | F.Hoffmann-La Roche Ag | Anticorps anti-igg1 humaine |
EP2671074A1 (fr) | 2011-02-02 | 2013-12-11 | F. Hoffmann-La Roche AG | Support de colonne chromatographique |
CN103702682A (zh) | 2011-04-21 | 2014-04-02 | 科罗拉多州立大学董事会法人团体 | 治疗视神经脊髓炎的组合物和方法 |
NZ783258A (en) | 2012-08-21 | 2023-06-30 | Regeneron Pharma | Methods for treating or preventing asthma by administering an il-4r antagonist |
TWI697334B (zh) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
SI3010539T1 (sl) | 2013-06-21 | 2019-11-29 | Regeneron Pharma | Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R |
BR112015032960B1 (pt) | 2013-07-04 | 2021-01-05 | F. Hoffmann-La Roche Ag | imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
WO2015091911A2 (fr) | 2013-12-20 | 2015-06-25 | Intervet International B.V. | Anticorps dirigés contre la pd-1 canine |
IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by adding an IL-4R antagonist |
AU2015222951B2 (en) | 2014-02-28 | 2020-06-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an IL-4R antagonist |
CA2961987A1 (fr) | 2014-09-30 | 2016-04-07 | Intervet International B.V. | Anticorps pd-l1 de liaison a pd-l1 canin |
WO2016077675A1 (fr) | 2014-11-14 | 2016-05-19 | Sanofi Biotechnology | Méthodes de traitement de la sinusite chronique avec polypose nasale par administration d'un antagoniste d'il-4r |
ES2897965T3 (es) * | 2015-08-21 | 2022-03-03 | Hoffmann La Roche | Procedimiento para la reducción de proteínas de célula huésped en cromatografía de afinidad |
WO2017032686A1 (fr) | 2015-08-21 | 2017-03-02 | F. Hoffmann-La Roche Ag | Procédé de réduction de protéines de cellules hôtes dans la chromatographie d'affinité |
US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
WO2018011405A1 (fr) * | 2016-07-15 | 2018-01-18 | Universität Zürich | Anticorps il-13r alpha1 pour dans le traitement de l'inflammation atopique, de la septicémie et de la neutropénie. |
EP3506931B1 (fr) | 2016-09-01 | 2024-07-31 | Regeneron Pharmaceuticals, Inc. | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
CA3045296A1 (fr) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Procedes, dispositifs et systemes de detection du tractus gastro-intestinal |
WO2018183932A1 (fr) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Traitement d'une maladie du tractus gastro-intestinal à l'aide d'un inhibiteur d'il-13 |
US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
EP3703818B1 (fr) | 2017-10-30 | 2023-11-01 | Sanofi Biotechnology | Antagoniste d'il-4r pour son utilisation dans le traitement ou la prévention de l'asthme |
JOP20200206A1 (ar) | 2018-03-21 | 2020-08-27 | Alx Oncology Inc | أجسام مضادة لألفا بروتين منظم للإشارة وطرق لاستخدامها |
MA52624A (fr) | 2018-05-13 | 2021-03-24 | Regeneron Pharma | Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r |
WO2020106757A1 (fr) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Dispositif ingérable pour administrer un agent thérapeutique au tube digestif |
EP3941589A1 (fr) | 2019-03-21 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie |
EP3947457A1 (fr) | 2019-03-26 | 2022-02-09 | ASLAN Pharmaceuticals Pte Ltd | Traitement faisant intervenir un anticorps anti-il-13r ou un fragment de liaison de celui-ci |
AU2020325021B2 (en) | 2019-08-05 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
US12090201B2 (en) | 2019-08-05 | 2024-09-17 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody |
WO2021119482A1 (fr) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal |
WO2022186773A1 (fr) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DE LA DERMATITE ATOPIQUE À L'AIDE D'UN ANTICORPS ANTI-IL-13Rα1 OU D'UN FRAGMENT DE LIAISON ASSOCIÉ CHEZ UNE POPULATION ALLERGIQUE |
WO2022186772A1 (fr) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DE LA DERMATITE ATOPIQUE À L'AIDE D'UN ANTICORPS ANTI-IL-13Rα1 OU D'UN FRAGMENT DE LIAISON ASSOCIÉ |
WO2023048650A1 (fr) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DU PRURIT FAISANT INTERVENIR UN ANTICORPS ANTI-IL13Rα1 OU UN FRAGMENT DE LIAISON DE CELUI-CI |
WO2023048651A1 (fr) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Procédé de traitement de la dermatite atoptique modérée à grave |
WO2023075702A1 (fr) | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Formulation d'anticorps anti-il-13r |
WO2024043837A1 (fr) | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | Formulation d'anticorps anti-il13r à haute concentration |
WO2024054157A1 (fr) | 2022-09-06 | 2024-03-14 | Aslan Pharmaceuticals Pte Ltd | Traitement de la perte de sommeil ou des troubles du sommeil chez des patients atteints de dermatite |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5614191A (en) | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
JP4224135B2 (ja) | 1995-10-23 | 2009-02-12 | ズィナイス セラピューティックス ピーティーワイ.エルティーディー. | 新規なヘモポエチン受容体およびそれをコードする遺伝子配列 |
US5843659A (en) * | 1996-03-21 | 1998-12-01 | Apoptosis Technology, Inc. | Apoptosis gene EI24, compositions, and methods of use |
JPWO2003046009A1 (ja) * | 2001-11-27 | 2005-04-07 | 持田製薬株式会社 | 抗IL13レセプターα1中和抗体 |
AR037756A1 (es) * | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
WO2003080675A2 (fr) * | 2002-03-22 | 2003-10-02 | Amrad Operations Pty Ltd | Anticorps monoclonal contre le recepteur alpha1 de l'interleukine 13 (il-13ra1) |
US7625699B2 (en) * | 2003-03-10 | 2009-12-01 | Celera Corporation | Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof |
GEP20146050B (en) * | 2003-07-15 | 2014-03-10 | Medarex Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
-
2005
- 2005-12-30 TW TW097137970A patent/TW200902555A/zh unknown
- 2005-12-30 TW TW094147847A patent/TWI306862B/zh not_active IP Right Cessation
-
2006
- 2006-01-02 AT AT06706157T patent/ATE513855T1/de not_active IP Right Cessation
- 2006-01-02 CA CA2592614A patent/CA2592614C/fr not_active Expired - Fee Related
- 2006-01-02 BR BRPI0606368-3A patent/BRPI0606368A2/pt not_active IP Right Cessation
- 2006-01-02 AU AU2006204480A patent/AU2006204480B2/en not_active Expired - Fee Related
- 2006-01-02 KR KR1020077015296A patent/KR100934894B1/ko not_active IP Right Cessation
- 2006-01-02 EP EP06706157A patent/EP1836226B1/fr active Active
- 2006-01-02 RU RU2007129676/10A patent/RU2413736C2/ru not_active IP Right Cessation
- 2006-01-02 JP JP2007548835A patent/JP5086098B2/ja not_active Expired - Fee Related
- 2006-01-02 WO PCT/EP2006/000005 patent/WO2006072564A1/fr active Application Filing
- 2006-01-02 NZ NZ556126A patent/NZ556126A/en not_active IP Right Cessation
- 2006-01-02 MX MX2007008128A patent/MX2007008128A/es active IP Right Grant
- 2006-01-02 SG SG2009087206A patent/SG172504A1/en unknown
- 2006-01-03 US US11/325,197 patent/US7807158B2/en not_active Expired - Fee Related
- 2006-01-03 AR ARP060100010A patent/AR051888A1/es unknown
-
2007
- 2007-06-25 IL IL184205A patent/IL184205A0/en unknown
- 2007-06-26 CR CR9209A patent/CR9209A/es not_active Application Discontinuation
- 2007-07-06 MA MA30048A patent/MA29226B1/fr unknown
- 2007-07-17 NO NO20073655A patent/NO20073655L/no not_active Application Discontinuation
-
2008
- 2008-06-23 HK HK08106940.0A patent/HK1112006A1/xx not_active IP Right Cessation
-
2010
- 2010-07-26 US US12/843,225 patent/US20110086026A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP5086098B2 (ja) | 2012-11-28 |
AU2006204480B2 (en) | 2011-06-09 |
MX2007008128A (es) | 2007-07-20 |
AR051888A1 (es) | 2007-02-14 |
EP1836226A1 (fr) | 2007-09-26 |
BRPI0606368A2 (pt) | 2009-06-23 |
CA2592614A1 (fr) | 2006-07-13 |
US7807158B2 (en) | 2010-10-05 |
KR20070091180A (ko) | 2007-09-07 |
US20110086026A1 (en) | 2011-04-14 |
WO2006072564A1 (fr) | 2006-07-13 |
ATE513855T1 (de) | 2011-07-15 |
TWI306862B (en) | 2009-03-01 |
RU2413736C2 (ru) | 2011-03-10 |
CR9209A (es) | 2007-08-28 |
TW200635945A (en) | 2006-10-16 |
MA29226B1 (fr) | 2008-02-01 |
NO20073655L (no) | 2007-08-02 |
IL184205A0 (en) | 2007-10-31 |
NZ556126A (en) | 2008-09-26 |
EP1836226B1 (fr) | 2011-06-22 |
JP2008526187A (ja) | 2008-07-24 |
RU2007129676A (ru) | 2009-02-10 |
AU2006204480A1 (en) | 2006-07-13 |
SG172504A1 (en) | 2011-07-28 |
TW200902555A (en) | 2009-01-16 |
KR100934894B1 (ko) | 2010-01-07 |
US20060263356A1 (en) | 2006-11-23 |
CA2592614C (fr) | 2015-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL184205A0 (en) | Antibodies against il-13 receptor alpha 1 and uses thereof | |
IL272883A (en) | Monoclonal antibodies and their uses | |
HK1105420A1 (en) | Interferon alpha receptor 1 antibodies and their uses | |
IL222922A (en) | Antibodies against neurophilin-1 and their use | |
IL182554A0 (en) | Anti-addl antibodies and uses thereof | |
IL187710A0 (en) | Anti-trkb monoclonal antibodies and uses thereof | |
IL189670A0 (en) | Trail receptor 2 polypeptides and antibodies | |
AP2008004471A0 (en) | Anti-Alpha2 Intergin antibodies and their uses | |
IL186071A0 (en) | Antibodies against ccr5 and uses thereof | |
IL188088A0 (en) | Cd19 antibodies and their uses | |
IL178277A0 (en) | Irta-5 antibodies and their uses | |
IL178356A0 (en) | Dr5 antibodies and uses thereof | |
IL188712A0 (en) | Novel anti-igf-ir antibodies and uses thereof | |
IL184024A0 (en) | Irta-5 antibodies and their uses | |
EP1940466A4 (fr) | Anticorps monoclonal anti-addl et leur utilisation | |
IL184659A0 (en) | Antibody variants and uses thereof | |
IL176755A0 (en) | M-csf-specific monoclonal antibody and uses thereof | |
ZA200703406B (en) | Anti-ADDL antibodies and uses thereof | |
ZA200802575B (en) | Trail receptor 2 polypeptides and antibodies | |
PL2068922T3 (pl) | Przeciwciała anty-IL-13R alfa1 i ich zastosowania | |
ZA200710916B (en) | CD19 antibodies and their uses | |
ZA200705382B (en) | Antibodies against IL-13 receptor alpha 1 and uses thereof | |
ZA200702281B (en) | IRTA-4 antibodies and their uses | |
GB0507219D0 (en) | Antibody and uses thereof | |
GB0507272D0 (en) | Antibody and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20150102 |